Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) Short Interest Down 99.2% in November

Provectus Biopharmaceuticals, Inc. (OTCMKTS:PVCT) saw a significant decrease in short interest in the month of November. As of November 15th, there was short interest totalling 500 shares, a decrease of 99.2% from the October 31st total of 65,600 shares. Based on an average trading volume of 595,800 shares, the short-interest ratio is presently 0.0 days.

Provectus Biopharmaceuticals Stock Performance

Shares of OTCMKTS:PVCT opened at $0.12 on Thursday. The business has a 50 day moving average price of $0.11 and a 200 day moving average price of $0.12. Provectus Biopharmaceuticals has a twelve month low of $0.04 and a twelve month high of $0.22.

About Provectus Biopharmaceuticals

Provectus Biopharmaceuticals, Inc, a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes in the United States. The company's lead molecule is rose bengal sodium (RBS). Its clinical development programs include PV-10 for the treatment of stage III and IV melanoma and different types of liver cancers; PH-10 for the treatment of psoriasis and atopic dermatitis, and skin inflammation; and PV-305 for the treatment of infectious keratitis.